Skip to content
MarketScale
‹ Back to IndustriesSciences

As Spaces Evolves into a “Normal Market”, How Will This Impact the Competition?

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration. In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · Space CommerceSpace Commerce ConsultingSpace EconomySpace Finance Community
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant for companies throughout the globe. As founder and CEO of Space Economy Rising, LLC, O’Connell speaks to the past and future of space commerce. With decades of experience working within government institutions, including the White House as well as speaking before US Congress committees on a variety of issues, O’Connell is uniquely positioned to provide insight into an industry that is both elusive and relevant.

When asked about his transition to the private sector, O’Connell spoke to his decision as follows:

“We’ve had a lot of folks talk to us over the last few years to say hey Kevin you just have to slow this all down. You have to slow all of this work down, especially in lower earth orbit. And, our view was that we looked very hard for data driven approaches to regulation we were going to regulate. What would be the analytic basis upon which we would do it.

We worked with the FCC when they issued their orbital debris mitigation guidelines to say okay what pieces of this rule are supported by what kinds of evidence. And, in a lot of cases there was a lot of wishful thinking but there wasn’t a lot of data rigorously collected to support that. And I would say that regulation that is uninformed and just based on wishful thinking can really do tremendous damage to an industry. So, you have to think about it that way. I think you do.”

This intriguing podcast goes on to explore O’Connell’s transition out of government and to what he is doing now in the private sector as well as what lessons he is bringing forward into his present business.

Of the many hats O’Connell wears, the most significant of his present contributions is in the field of space economy. This includes advising companies on

  • Space Industry
  • Technology
  • Space finance community
  • Basics that must be done as an early-stage company in this field
  • Competitors
  • Orbital debris mitigation strategies
  • Cyber security strategies
  • Investment Risk Management
  • And much more.

Tune in to learn from this renowned expert as the discussion covers everything from how he got to where he is to what he envisions for the future of space economy.

More in This Series

About the author

CB
Chris Blackerby

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby